Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: A realistic goal?

Treatments in Respiratory Medicine

Volumn 4, Issue 2, 2005, Pages 71-84

  Blackhall, Fiona H ^a   Shepherd, Frances A ^b   Albain, Kathy S ^c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; LOPERAMIDE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROCARBAZINE; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; TIRAPAZAMINE; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DYSPNEA; FEBRILE NEUTROPENIA; FLUID RETENTION; GRANULOCYTOPENIA; HEARING LOSS; HEART DEATH; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LUNG NON SMALL CELL CANCER; MALAISE; META ANALYSIS; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICROTUBULES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZINES;

EID: 18144392737     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200504020-00001     Document Type: Article

References (71)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004 Jan 22; 350 (4): 379-92
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16,1997 by the American Society of Clinical Oncology. J Clin Oncol 1997 Aug; 15 (8): 2996-3018
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995 Oct 7; 311 (7010): 899-909
4. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991 Sep; 9 (9): 1618-26
5. Bunn Jr PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998 May; 4 (5): 1087-100
6. Stephens RJ, Fairlamb D, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting [abstract]. Proc Am Soc Clin Oncol 2002; 21: 1161
7. Brown JM, Thorpe H, Napp V, et al. The Big Lung Trial Quality of Life Study: determining the effect of cisplatin-based chemotherapy for supportive care patients with non-small cell lung cancer (NSCLC) [abstract no.2533]. Proc Am Soc Clin Oncol 2003; 22: 630
8. National Cancer Institute: common terminology criteria for adverse events [online]. Available from URL: http//ctep.cancer.gov/reporting/ctc.html [Accessed: 2004 Dec 20]
9. Murry DJ. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997; 17: 1405
10. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17 (3): 1061-70
11. Hohneker JA. A summary of vinorelbine (Navelbine). Sem Oncol 1995; 22 Suppl. 5: 80
12. Hande KR. Chemotherapy. In: Minna JD, editor. Lung cancer: principles and practice. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2000: 270-83
13. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al. Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 1985 Mar 14; 312 (11): 692-700
14. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 Aug; 12 (8): 1535-40
15. Ettinger DS. Pemetrexed (Alimta): a new antifolate for non-small-cell lung cancer. Clin Lung Cancer 2002 Mar; 3 Suppl. 1: S22-5
16. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000 Mar; 18 (6): 1351-9
17. Williamson SK, Crowley JJ, Lara, PN, et al. S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) Trial [abstract no. 2502]. Proc Am Soc Clin Oncol 2003; 22: 622
18. Tannock IF. Experimental chemotherapy. In: Tannock IF, Hill RP, editors. The basic science of oncology. 2nd ed. New York: McGraw-Hill Inc., 1992: 338-59
19. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986 Jan; 4 (1): 14-22
20. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single-agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989 Nov; 7 (11): 1602-13
21. Lilenbaum RC, Langenberg P, Dickersin K. single-agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998 Jan 1; 82 (1): 116-26
22. Wozniak Al, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16 (7): 2459-65
23. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000 Oct 1; 18 (19): 3390-9
24. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000 Jan; 18 (1): 122-30
25. Le Chevalier T, Brisgand D, Soria JC, et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6 Suppl. 1: 8-11
26. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994 Jan; 5 (1): 37-42
27. Lilenbaum RC, Herndon J, List M, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness [abstract]. Proc Am Soc Clin Oncol 2002; 21: 2
28. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 2002 Jun; 29 (3 Suppl. 9): 50-4
29. Georgoulias V, Pallis AG, Kourousis C, et al. Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer 2003 Mar; 4 (5): 288-93
30. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292 (4): 470-84
31. Baggstrom MQ, Socinski MA, Hensing TA, et al. Addressing the optimal number of cytotoxic agents in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature [abstract no. 2510]. Proc Am Soc Clin Oncol 2003; 22: 624
32. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21 (17): 3207-13
33. Budman DR, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs 1998; 9 (8): 697-702
34. Kelly K, Crowley J, Bunn Jr PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001 Jul 1; 19 (13): 3210-8
35. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10; 346 (2): 92-8
36. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003 Aug 15; 21 (16): 3016-24
37. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003 Aug 15; 21 (16): 3025-34
38. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC 08975). J Clin Oncol 2003 Nov 1; 21 (21): 3909-17
39. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47 (1): 69-80
40. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 May; 18 (10): 2095-103
41. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004 Feb; 43 (2): 183-94
42. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000 Jun; 18 (12): 2354-62
43. Shepherd FA, Pereira JR, Von Pawel J, et al. A phase III study of pemetrexed vs, docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy [abstract]. Lung Cancer 2003; 41: S4
44. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003 Aug; 3 (4): 435-42
45. Raftopoulos H, Gralla RJ, D'Auria G, et al. Assessing the role of cisplatin dose and dose intensity (DI) in advanced non-small cell lung cancer (NSCLC): a comprehensive review of randomized trials 1992-2002 [abstract no. 2596]. Proc Am Soc Clin Oncol 2003; 22: 645
46. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001 Mar 1; 19 (5):1336-43
47. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002 Mar 1; 20 (5): 1335-43
48. Edelman MJ, Gandara DR, Lau DH, et al. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 2001 Jul 1; 92 (1): 146-52
49. Clark JI, Kancharla K, Qamar R, et al. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Lung Cancer 2001 Nov; 34 (2): 271-7
50. Edelman MJ, Clark JI, Chansky K, et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 2004; 10 (15): 5022-6
51. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003 Sep; 41 (3): 321-31
52. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002 Oct; 13 (10): 1539-49
53. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (145): 7068
54. Georgoulias V, Samonis G, Papadakis E, et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 2001 Dec; 34 Suppl. 4: S47-51
55. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002 Sep 1; 20 (17): 3578-85
56. D'Addario G, Pintilie M, Cerny T, et al. Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Lung Cancer 2003; 41 Suppl. 2: S68
57. Raftopoulos H, Gralla RJ, Nelli F, et al. Can survival differences be found among cisplatin, carboplatin, and non-platinum regimens? Results of a comprehensive review of chemotherapy in advanced non-small cell lung cancer (NSCLC) randomised trials including 12181 patients from 1992-2002. Lung Cancer 2003; 41 Suppl. 2: S68
58. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 Jun 15; 21 (12): 237-46
59. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 Oct 22; 290 (16): 2149-58
60. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib, in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract]. J Clin Oncol 2004; 22 (14S): 7022
61. AstraZeneca. Gefitinib (IRESSA) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. [press release]. 2004 Dec 17
62. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004 Mar 1; 22 (5): 777-84
63. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004 Mar 1; 22 (5): 785-94
64. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract]. J Clin Oncol 2004; 22 (14S): 7010
65. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib HC1 (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract]. J Clin Oncol 2004; 22 (14S): 7011
66. Miller VA, Herbst R, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HC1 (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. ASCO Annual Meeting Proceedings (2004) [abstract]. J Clin Oncol 2004; 22 (14S): 7061
67. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003 Aug; 41 Suppl. 1: S63-72
68. Leighl NB, Shepherd F, Paz-Ares L, et al. Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract]. Clin Oncol 2004; 22 (14S): 7038
69. Franklin WA, Carbone DP. Molecular staging and pharmacogenomics clinical implications: from lab to patients and back. Lung Cancer 2003; 41: S147-54
70. Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004 Feb; 31 (1 Suppl. 1): 20-7
71. Paez JG, Janne, PA, Lee JC, et al. EGER mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676): 1497-500